Scientists test First-Ever vaccine against dangerous strep bacteria in seniors

NCT ID NCT05782179

Summary

This study tested a new vaccine designed to protect against Group B Streptococcus (GBS) infections in adults aged 55 to 75. Researchers gave three doses of either the experimental vaccine or a placebo to 90 healthy, obese, or diabetic participants to check how safe it was and whether it triggered a protective immune response. The main goal was to see if the vaccine was well-tolerated and if people's bodies produced enough antibodies to potentially fight off the bacteria.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GROUP B STREPTOCOCCAL INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • University Hospital Ghent - Centrum voor Vaccinologie (CEVAC) department

    Ghent, 9000, Belgium

Conditions

Explore the condition pages connected to this study.